Argentina will begin to vaccinate young people between 12 and 17 years old with comorbidities from next week, according to the Government. It is about 900 thousand children who will be applied the doses of Moderna that were donated last week by the United States and that were recently approved in Europe for this age group by the European Medicines Agency.
From the Executive Power they assured that “the European Medicine Agency approved today the Moderna laboratory vaccine for minors between 17 and 12 years old. Said authorization enables the start in Argentina of vaccination for young people, adolescents and children with risk factors. “And they added that” the strategic decision of the national government to have 3,500,000 of Moderna vaccines donated by the USA was successful ”.
On the other hand, they announced that “next Tuesday, at a COFESA meeting, the health ministers of the entire country will define the groups and the implementation strategy and will formalize the start of vaccination for this prioritized group throughout the country. Adolescents between 12 and 17 with comorbidities will begin to be vaccinated, a population estimated at 900,000 people ”.
It should be noted that Argentina received 3.5 million doses of Moderna donated by the United States last week, part of which the Government will apply to adolescents between 12 and 17 years of age with risky conditions. The Minister of Health, Carla Vizzotti, had advanced yesterday “that in the next few days there will be news” in relation to this laboratory.
“Once approved by the FDA (United States Food and Drug Administration) and the EMA (European Medicines Agency), as they are highly vigilant regulatory entities, Argentina feels that it can give authorization for emergency use and in this particular situation, with the authorization of the country of origin, is sufficient “, had indicated Vizzotti.
Moderna’s vaccine developed with messenger RNA technology is administered in two doses and, according to the World Health Organization (WHO), can be stored at 2 ° C to 8 ° C for 30 days. In addition, it demonstrated an efficacy of 94.1% against symptomatic Covid-19, presented good results in the adolescent population and generated neutralizing titers against the new variants of the virus in immunized people, according to clinical trials.
On May 25, Moderna announced that its coronavirus vaccine is “highly effective” in adolescents between the ages of 12 and 17, according to the full results of the TeenCOVE clinical trial. More than 3,700 adolescents between the ages of 12 and 17 in the United States participated in that study, of whom two-thirds received the vaccine and one-third placebo.
“After two doses, no cases of Covid-19 were observed in the vaccinated group (…) against four cases in the placebo group, resulting in a vaccine effectiveness of 100% 14 days after the second dose.” Moderna said in its statement. The company also started a study in 6,750 children 6 months to 11 years (KidCOVE) whose results it has not yet presented.